Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia

AIDS. 2009 Jun 19;23(10):1287-90. doi: 10.1097/QAD.0b013e32832d0792.

Abstract

The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is currently unclear. We identified all patients who were treated with trimetrexate and folinic acid who failed 7 or more days of cotrimoxazole, clindamycin-primaquine or dapsone-trimethoprim between 1996 and 2006. Trimetrexate was tolerated in 100% of cases with no treatment termination secondary to adverse drug reactions. Despite severe disease, 71% of patients were alive after 12 weeks.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Antifungal Agents / therapeutic use*
  • Drug Evaluation
  • Drug Therapy, Combination
  • Female
  • HIV-1
  • Humans
  • Leucovorin / therapeutic use*
  • Male
  • Middle Aged
  • Pneumocystis carinii*
  • Pneumonia, Pneumocystis / drug therapy*
  • Retrospective Studies
  • Salvage Therapy / methods
  • Treatment Outcome
  • Trimetrexate / therapeutic use*

Substances

  • Antifungal Agents
  • Leucovorin
  • Trimetrexate